45 recruiting, 33 completed, 32 active not recruiting, 25 unknown. 159 Phase 2, 32 Phase 1, 6 Phase 3.
Follow osimertinib: new trials by email Literature Review of osimertinib trials Research Report on osimertinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib Capivasertib in combination with Osimertinib - Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell) | Phase 1 / Phase 2 | Not yet recruiting | Shanxi Province Cancer Hospital | 53 | 2026-12-08 | 2026-11-19 |
| Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel - Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Phase 2 | Recruiting | NYU Langone Health | 60 | 2026-10-01 | 2026-10-15 |
| A Phase 2 Study of ABSK043 Combined With Osimertinib ABSK043 in combination with Osimertinib - Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive | Phase 2 | Not yet recruiting | Abbisko Therapeutics Co, Ltd | 72 | 2026-08-31 | 2026-07-17 |
| A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) BL-B01D1, Osimertinib, Carboplatin - Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 90 | 2026-07-24 | 2026-08-03 |
| A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) SKB571 for injection, Osimertinib, Furmonertinib - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 150 | 2026-07-15 | 2026-09-02 |
| A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer AK146D1 for injection, AK112 Injection, Platinum chemotherapy - Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Akeso | 348 | 2026-07-10 | 2026-07-14 |
| Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. ALK202 for injection, Osimertinib Mesylate Tablets, Ivonescimab Injection - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 252 | 2026-06-30 | 2026-05-22 |
| Boosting Osimertinib Blood Brain Barrier Penetration Osimertinib & febuxostat - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Maastricht University Medical Center | 7 | 2026-06-01 | 2026-06-05 |
| A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer ANS014004 + PLB1004, ANS014004 + Osimertinib - Non-Small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability Company | 253 | 2026-06-01 | 2025-12-16 |
| Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors IBI3005, Sintilimab, Bevacizumab biosimilar - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 282 | 2026-06-01 | 2026-05-28 |
| A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer Ivonescimab, Dato-DXd, Osimertinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 66 | 2026-04-09 | 2026-07-13 |
| Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study Osimertinib - Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 60 | 2026-04-01 | 2026-10-28 |
| Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer Sacituzumab Tirumotecan, Osimertinib - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 30 | 2026-03-30 | 2026-08-20 |
| Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases Osimertinib, Stereotactic Radiosurgery - Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Cho Ray Hospital | 41 | 2026-02-27 | 2026-11-12 |
| Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 60 | 2026-02-19 | 2026-04-20 |
| Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer Local ablative therapy, Osimertinib alone - Lung Cancer (NSCLC) | Phase 2 | Recruiting | Chinese University of Hong Kong | 64 | 2026-02-11 | 2026-02-12 |
| Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O, Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer - Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 74 | 2026-01-01 | 2026-04-01 |
| A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy Osimertinib + Sacituzumab Tirumotecan, Osimertinib - Non Small Cell Lung Cancer | Phase 2 | Recruiting | Guangdong Association of Clinical Trials | 120 | 2025-12-15 | 2026-05-26 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Standard of Care, Osimertinib - Non-Small Cell Lung Cancer, c-MET | Phase 2 / Phase 3 | Recruiting | AbbVie | 490 | 2025-12-10 | 2026-10-05 |
Showing 20 of 159. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (111) · Lung Neoplasms (35) · Brain Neoplasms (7) · Neoplasm Metastasis (6) · Neoplasms (5) · Adenocarcinoma of Lung (3) · Breast Neoplasms (3) · Carcinoma, Squamous Cell (3) · Colorectal Neoplasms (3) · Meningeal Carcinomatosis (3) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Bronchial Neoplasms (2) · Carcinoma (2) · Hematologic Neoplasms (2)
AstraZeneca (14) · National Cancer Institute (NCI) (6) · Tianjin Medical University Cancer Institute and Hospital (5) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (4) · Memorial Sloan Kettering Cancer Center (4) · Samsung Medical Center (4) · Sichuan Baili Pharmaceutical Co., Ltd. (4) · Dana-Farber Cancer Institute (3) · Guangdong Association of Clinical Trials (3) · Jonsson Comprehensive Cancer Center (3) · Shanghai JMT-Bio Inc. (3) · Sun Yat-sen University (3) · AbbVie (2) · ETOP IBCSG Partners Foundation (2) · Hunan Province Tumor Hospital (2)
China (61) · United States (55) · South Korea (29) · Spain (19) · Taiwan (15) · Italy (14) · Singapore (11) · France (10) · Netherlands (10) · Germany (8) · Australia (7) · Canada (7) · Japan (7) · Belgium (6) · Hong Kong (6)
Helena Yu, MD (3) · Li Zhang (2) · Liu Anwen, Phd (2) · Nir Peled, MD PhD FCCP (2) · Sarah B Goldberg (2) · Alessandro Morabito, MD (1) · Amanda Tufman, Prof. Dr. (1) · Anjali Rohatgi, M.D., Ph.D. (1) · Arya Amini (1) · Athanasios Kotsakis, PhD (1) · Azam Ghafoor, M.D. (1) · Caicun Zhou (1) · Caicun Zhou, Doctorate (1)
PMID 25175099, PMID 27959700, PMID 29151359, PMID 29293889, PMID 30512189, PMID 31085043, PMID 31345012, PMID 32027845, PMID 40311309, PMID 41534788, PMID 17374728, PMID 17894407, PMID 20595147, PMID 21784628, PMID 22487432, PMID 24644001, PMID 24893891, PMID 25695221, PMID 25923549, PMID 26181354, PMID 26473643, PMID 26494259, PMID 26586415, PMID 27354477, PMID 27435396, PMID 27751847, PMID 28105214, PMID 28408243, PMID 28577957, PMID 28627678, PMID 28751247, PMID 28765329, PMID 28841389, PMID 28857200, PMID 28881293, PMID 29290249, PMID 29307353, PMID 29363250, PMID 29438373, PMID 29700687, PMID 29782558, PMID 29858027, PMID 30059262, PMID 30073261, PMID 30975627, PMID 31108248, PMID 31648999, PMID 31751012, PMID 31825714, PMID 32200138
2023 (4), 2015 (3), 2017 (3), U10CA180820 (3), 2014 (2), 2018 (2), 2025 (2), 2016 (1), 2019 (1), P30CA033572 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186689 (1), UM1CA186712 (1)